AVEO Pharmaceuticals (STU:VPA1) Short-Term Debt : €11.61 Mil (As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Short-Term Debt?

AVEO Pharmaceuticals's Short-Term Debt for the quarter that ended in Sep. 2022 was €11.61 Mil.

AVEO Pharmaceuticals's quarterly Short-Term Debt increased from Mar. 2022 (€0.00 Mil) to Jun. 2022 (€4.90 Mil) and increased from Jun. 2022 (€4.90 Mil) to Sep. 2022 (€11.61 Mil).

AVEO Pharmaceuticals's annual Short-Term Debt declined from Dec. 2019 (€8.61 Mil) to Dec. 2020 (€0.87 Mil) and declined from Dec. 2020 (€0.87 Mil) to Dec. 2021 (€0.00 Mil).

AVEO Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for AVEO Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Short-Term Debt Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Debt

Get a 7-Day Free Trial

2.86

8.61

0.87

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	4.90	11.61

AVEO Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

AVEO Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines